Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD) - Full Text View

Purpose

The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.

Condition	Intervention	Phase
Esophageal Reflux	Drug: Rabeprazole	Phase II

MedlinePlus related topics:

Esophagus Disorders GERD

ChemIDplus related topics:

E 3810

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment

Official Title:	Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD)

Further study details as provided by University of Kansas:

Primary Outcome Measures:

Measure of concentration and output of esophageal mucus in esophageal secretion before and after 8 weeks of therapy with rabeprazole

Secondary Outcome Measures:

Esophageal mucin measurement comparisons on samples collected before and after rabeprazole therapy

Enrollment:	24
Study Start Date:	May 2005
Study Completion Date:	May 2007

Detailed Description:

Enrolled patients will undergo collection of salivary and esophageal secretions. Subsequently, all patients will receive rabeprazole (20mg QD) for 8 weeks and will be re-endoscoped to confirm complete healing of reflux esophagitis. In patients with completely healed reflux esophagitis the second collection of salivary and esophageal secretion will be implemented. In both secretions, adequately coded for the laboratory Research Fellow (blinded in terms of which sample is collected before and which after treatment with rabeprazole) the content of mucin will be measured using commercially available assay and its secretion expressed in units per minute of collection time.

Eligibility

Ages Eligible for Study:	19 Years to 79 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria: 24 patients with endoscopically confirmed reflux esophagitis (Grades A-D according to LA classification) in patients with chronic symptoms of GERD (heartburn with or without regurgitation) between the age of 19 and 79, 12M & 12F, will be included.

Exclusion criteria: History of GI surgery, primary esophageal motor disorders, any systemic disease, history of drug or alcohol abuse, pregnancy or nursing, allergy to the same drug class as rabeprazole, the need for any concurrent therapy that affects salivary secretion (causing so-called "dry mouth syndrome").

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00222170

Locations


United States, Kansas
	University of Kansas Medical Center
	Kansas City, Kansas, United States, 66160

Sponsors and Collaborators

University of Kansas

PriCara, Unit of Ortho-McNeil, Inc.

Eisai Inc.

Investigators


Principal Investigator:	Jerzy Sarosiek, PhD	University of Kansas

Principal Investigator:	Mojtaba S. Olyaee, MD	University of Kansas

More Information

Study ID Numbers:	RE Study
First Received:	September 13, 2005
Last Updated:	August 1, 2007
ClinicalTrials.gov Identifier:	NCT00222170
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Deglutition Disorders

Esophageal Motility Disorders

Digestive System Diseases

Esophageal disorder

Gastrointestinal Diseases

Esophageal Diseases

Gastroesophageal Reflux

Rabeprazole

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Anti-Ulcer Agents

Gastrointestinal Agents

Enzyme Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 03, 2008

Sponsors and Collaborators:	University of Kansas PriCara, Unit of Ortho-McNeil, Inc. Eisai Inc.
Information provided by:	University of Kansas
ClinicalTrials.gov Identifier:	NCT00222170